Shire is reportedly looking at buying U.S.-based NPS Pharmaceuticals.
Shire is reportedly looking at buying U.S.-based NPS Pharmaceuticals.
The news comes just a couple of months after AbbVie dropped its takeover offer for Shire.
Shire received a US$1.64-billion breakup fee after that deal collapsed.
NPS Pharmaceuticals’ current therapeutic areas of focus are gastrointestinal disease and endocrine disorders.
For the full story, visit the Bloomberg News website.
Read:
Satwik Misra, CFA, MBA will be stepping into the newly created role of Director, Consultant Relationships & Business Initiatives, reflecting the continued growth and expansion...
On Oct. 18 in Toronto, the 2024 Healthy Outcomes Conference brought together nearly 140 benefits plan sponsors, experts and other industry thought leaders to exchange...
Plan sponsors are facing the perfect storm of rising benefits costs, a surge in chronic disease prevalence and fierce competition for top talent. All the...
While migraine is a complex neurological condition that can significantly impact patients’ quality of life and ability to work, it’s also poorly understood and often...
While nine in 10 (85 per cent) employers that reported decreased employee productivity over the past year cited burnout as a major problem, investing in...
Joey Restaurant Group is using an internal educational program to teach employees the soft skills of leadership and assist in their career development. By focusing on...
The average funded position of defined benefit pension plans in Ontario was 121 per cent in the third quarter of 2024, down just two per...
As plan sponsors contend with high utilization of their drug plans and a host of costly new drugs coming to market, a variety of cost-containment...